ASCO Annual Meeting: Hematology

Data were presented at ASCO 2019 on the link between current and former smoking on treatment outcomes in AML in treatment-naive patients.

A phase I study of a CAR T-cell therapy showed success in refining cell dosing and adverse event management protocols in patients with relapsed/refractory ALL.

New data from the CASSIOPEIA trial evaluated the use of daratumumab in addition to bortezomib/thalidomide/dexamethasone after ASCT in multiple myeloma.

Researchers studied the Fc-enhanced, humanized anti-CD19 antibody MOR208 combined with lenalidomide in relapsed/refractory large B-cell lymphoma.

The MAGNIFY phase IIIb trial looked at the efficacy and safety of lenalidomide combined with rituximab in relapsed/refractory indolent non-Hodgkin lymphoma.

Research presented at ASCO 2019 posited that multiple socioeconomic factors make a real difference in overall survival.

CAR T-cell therapy with bb2121 induced deep, long-lasting responses in patients with heavily pretreated MM.

A case series of rare peripheral T-cell lymphoma that is associated with breast implants found that most cases have an indolent clinical course.

In the randomized phase III iNNOVATE trial, adding ibrutinib to rituximab significantly improved PFS in patients with Waldenström macroglobulinemia.

In CAPTIVATE, first-line ibrutinib plus venetoclax yielded a high rate of undetectable residual disease, without new safety signals, in chronic lymphocytic leukemia.

In TRANSCEND NHL 001, the CD19-directed 4-1BB CAR T-cell product lisocabtagene maraleucel yielded durable responses in heavily pretreated R/R DLBCL.

In MMY1001, median PFS was 14.1 months and median OS was 21.1 months in patients with lenalidomide-refractory myeloma treated with daratumumab/carfilzomib.

A once-weekly regimen of carfilzomib plus dexamethasone improved response and delayed progression better than a twice-weekly regimen in R/R MM.

This approach may lead to better understanding of risk-mitigation strategies, and perhaps better outcomes in patients with secondary AML.

Unconventional strategies and targeted therapeutics may be required to overcome the adverse risks associated with TP53-mutated AML.

OPTIMISMM is the only phase III trial to show a significant PFS benefit in R/R MM patients with prior exposure to lenalidomide.

Therapy with CAR T cells may benefit patients with highly refractory multiple myeloma, said U Penn’s Adam Cohen at ASCO 2018.

Risk stratification is leading to increasing numbers of new molecular targets in multiple myeloma.

Joshua Brody discusses ECHELON-1 and its subanalyses, the results of which are anticipated to change the management of Hodgkin lymphoma.

This video examines the targeting of IDH1/IDH2 mutations in patients with relapsed or refractory acute myeloid leukemia.

In patients with newly diagnosed multiple myeloma, elotuzumab plus bortezomib, lenalidomide, and dexamethasone was associated with significant toxicity and infections.

The novel IDH2-inhibitor enasidenib was well tolerated and offered durable responses in a phase I trial of relapsed or refractory acute myeloid leukemia patients with an IDH2 mutation.

Cardiovascular adverse events are more than twice as frequent in carfilzomib arms of randomized controlled trials in multiple myeloma, according to a systematic review and meta-analysis of 24 studies.

In this interview we discuss how relapse in multiple myeloma manifests and treatment options for relapsed/refractory patients.

Despite immune-related adverse events, concurrent ibrutinib and anti-CD19 CAR T-cell therapy may improve response rates in patients with chronic lymphocytic leukemia.

The combination of the anti-CD38 monoclonal antibody isatuximab with pomalidomide/dexamethasone had an acceptable and manageable safety profile in patients with relapsed or refractory multiple myeloma.

A fifth course of cytarabine chemotherapy resulted in improved overall and disease-free survival in pediatric patients with low-risk acute myeloid leukemia.

Among high-risk multiple myeloma patients, post-ASCT immunization with the Wilms tumor 1 peptide mixture galinpepimut-S is well tolerated and is associated with promising progression-free survival.

This video presents updated results of two phase III trials in relapsed or refractory multiple myeloma, showing the impact of daratumumab combinations across cytogenetic risk groups.

Adding daratumumab to standard of care is a feasible alternative to autologous stem cell transplantation with standard regimens in multiple myeloma patients.